Novartis Ophthalmics
  Novartis Pharma US

 
CHANGE TEXT SIZE  Decrease Font Size Increase Font Size
Helpful Hints
Help your patients understand how their eyes work, how to care for their eyes, their children's eyes, and what tests they may receive during an eye exam.
Find Out How >

Advancing Excellence in Ophthalmology

Press Releases



The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis' Web site for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as being current or accurate after their publication dates.
 
  > 03/01/2005 Novartis Ophthalmics Announces National Visudyne Access Network
  > 02/07/2005 Novartis obtains rights from Otsuka to develop new treatment for dry eye
  > 01/25/2005 Novartis and Schering AG finalize commercialization agreement for novel oral angiogenesis inhibitor PTK787
  > 05/10/2004 Visudyne® launched in Japan for treatment of age-related macular degeneration
  > 04/22/2004 Quarterly Results: Novartis Outpaces Market
  > 04/01/2004 QLT Announces New Medicare Policy Takes Effect Expanding Reimbursement For Visudyne®
  > 03/16/2004 QLT Announces Visudyne® To Receive Centers For Medicare and Medicaid Exception on Allowable Reimbursement Level
> 01/29/2004 QLT and Novartis Announce Centers For Medicare and Medicaid Services Intend to Reimburse Visudyne® For Occult and Minimally Classic Lesions in AMD

Back to Top


ABOUT US
Our mission and vision
Read More >

PRODUCTS
Find information on a specific eye care product
Read More >



Home  |  Professional Main Page  |  About Ophthalmics  |  Products
Eye Diseases & Disorders  |  Patient Education Library
Patient Assistance Program  |  Press Releases

Contact Us  |  Site Guide  |  Site Map

Novartis Pharma US Use of website is governed by the Terms of Use and Privacy Statement .
Copyright ©2007
Novartis Pharmaceuticals Corporation. All rights reserved.